By Josh Beckerman
Werewolf Therapeutics Inc., which is developing cancer drugs using its Predator protein engineering technology, filed for an initial public offering.
The Cambridge, Mass., company has applied for a Nasdaq Global Market listing under symbol HOWL.
Werewolf said in January that it completed its $72 million Series B financing, led by RA Capital Management. According to the filing, RA Capital has a 11.25% stake. MPM Capital owns 20.75%, and an oncology fund that MPM raised in partnership with UBS Group AG holds 11.56%.
In February, Werewolf named Tim Trost chief financial officer.
Write to Josh Beckerman at firstname.lastname@example.org
(END) Dow Jones Newswires
April 08, 2021 18:10 ET (22:10 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.